Elanco Animal Health v. Pet IQ — Voluntary Dismissal After 26 Days
Elanco Animal Health sued Pet IQ over alleged infringement of US7910122B2 in connection with Pet Armor Extend products. Filed in the Florida Middle District Court, the case ended in a voluntary dismissal without prejudice just 26 days after filing — among the fastest closures seen at this court level.
A 26-day patent sprint: Elanco files, then retreats on Pet Armor Extend
On August 22, 2025, Elanco Animal Health, Inc. filed an infringement action against Pet IQ, LLC in the United States District Court for the Middle District of Florida, asserting US7910122B2 against Pet IQ’s Pet Armor Extend product line. Elanco, a major animal health company, and Pet IQ, a pet wellness and veterinary services company, are direct commercial competitors in the over-the-counter animal health market. The case was assigned in Orlando, Florida.
The case closed on September 17, 2025 — just 26 days after filing — when Elanco filed a Notice of Voluntary Dismissal without prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). The court directed the Clerk to close the case. Critically, the dismissal was without prejudice, meaning Elanco retains the right to refile the same claims against Pet IQ in the future. No defendant answer or counterclaim had been filed, which is a prerequisite for unilateral dismissal under this rule.
A 26-day lifecycle is exceptionally short, suggesting the dismissal may reflect early-stage settlement discussions, a licensing negotiation, a strategic recalibration, or a decision to pursue a different enforcement avenue. The public record does not disclose the reason for the rapid withdrawal. Because the dismissal was without prejudice, the underlying infringement dispute over Pet Armor Extend products may not be fully resolved, and the competitive tension between these parties in the animal health space could resurface.
Filing to Voluntary dismissal in 26 days
26 days — well below the district court median case duration of 2+ years
Voluntarily dismissed: what Rule 41 means for both parties
Rule 41(a)(1)(A)(i): plaintiff’s right to exit before answer
Federal Rule of Civil Procedure 41(a)(1)(A)(i) permits a plaintiff to dismiss a case without a court order before the defendant has served an answer or a motion for summary judgment. Here, Pet IQ had not yet answered, so Elanco could file the notice unilaterally. The court’s order simply directs the Clerk to close the case — it is an administrative step, not a judicial determination on the merits.
No merits adjudicationWithout prejudice confirmed — refiling door stays open
The verdict text explicitly states the dismissal is without prejudice. This distinguishes the outcome from a with-prejudice dismissal, which would bar Elanco from relitigating the same claims. Here, Elanco preserves its right to refile US7910122B2 claims against Pet IQ at any time before the applicable statute of limitations expires. The public record does not disclose whether any side agreement, licence, or settlement accompanied the dismissal.
Refiling remains possiblePet IQ avoids a merits fight — for now
Pet IQ obtained closure of the immediate action without having to mount a defence, file invalidity counterclaims, or incur substantial litigation costs. However, because the dismissal is without prejudice, Pet IQ cannot treat this as a final resolution. The continued commercial sale of Pet Armor Extend products may remain subject to future assertion of US7910122B2. Pet IQ’s legal exposure is deferred, not eliminated.
Exposure deferred, not resolvedOTC animal health IP: competitive pressure remains live
The rapid dismissal without prejudice is consistent with either a confidential commercial resolution or a deliberate pause in enforcement strategy. For the broader OTC animal health and pet parasite treatment market, the case signals that Elanco is willing to assert US7910122B2 aggressively. Competitors and private-label manufacturers in this space should treat this filing as an indicator of active IP enforcement posture, even absent a final judgment.
Enforcement posture signalledFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Elanco Animal Health, Inc. | Company | Animal health pharmaceutical company — holder of US7910122B2Search in Eureka ↗ |
| Defendant | Pet IQ, LLC | Company | Pet wellness and OTC animal health products company; maker of Pet Armor ExtendSearch in Eureka ↗ |
| Plaintiff counsel | Elizabeth Grace McIntosh | Attorney | Counsel for Elanco Animal Health, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Gregory F. Ahrens | Attorney | Counsel for Elanco Animal Health, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Nina Greene | Attorney | Counsel for Elanco Animal Health, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Venable LLP | Law Firm | Representing Elanco Animal Health, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Wood, Herron & Evans LLP | Law Firm | Representing Elanco Animal Health, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Florida Middle District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order is purely administrative — it confirms the procedural prerequisites of Rule 41(a)(1)(A)(i) were met and directs the Clerk to close the file. No claim construction, validity finding, or infringement determination was made. The absence of a defendant answer is a critical detail: it confirms Elanco acted unilaterally and that no counterclaims or invalidity positions were formally asserted. The without-prejudice designation is the operative legal consequence for both parties.
US7910122B2 — animal health parasite treatment formulations
US7910122B2 (application number US11/631089) is asserted by Elanco Animal Health in connection with Pet Armor Extend products — an over-the-counter parasite treatment line for companion animals. The patent sits within the animal health pharmaceutical domain, covering formulations or methods directed at parasite control. As an issued US patent with a B2 designation, it reflects a granted patent that has undergone at least one round of post-grant prosecution, suggesting the claims have been examined and refined.
For the OTC animal health market, a granted patent in parasite treatment formulations carries significant commercial weight — private-label and generic competitors must navigate the claim scope before commercialising similar products. Elanco’s decision to assert this patent against Pet IQ’s Pet Armor Extend line suggests the patent is considered a meaningful competitive moat. IP teams at animal health companies, pet product manufacturers, and retailers sourcing private-label parasite treatments should assess their exposure to this patent’s claim scope.
Should you run an FTO against US7910122B2?
Any company developing, manufacturing, or distributing OTC companion animal parasite treatment products — particularly those competing with branded Elanco lines — should treat US7910122B2 as a priority FTO target. This case confirms Elanco is willing to enforce the patent in federal court. Retailers sourcing private-label Pet Armor Extend equivalents and generic animal health formulators are especially exposed given the without-prejudice dismissal leaves the claim live.
PatSnap Eureka’s FTO Search Agent can map the full claim scope of US7910122B2, identify design-around opportunities, flag related family members and continuation risk, and surface any co-pending applications in Elanco’s portfolio that may extend protection. Eureka’s prosecution history analysis provides the fastest path to understanding which claim elements were narrowed during examination — critical for any non-infringement opinion.
Run a freedom-to-operate analysis on US7910122B2 to assess your product’s exposure
Run FTO in Eureka →Similar OTC animal health patent infringement cases in US district courts
Browse comparable animal health and parasite treatment patent infringement filings in US district courts, including Florida Middle District actions involving pharmaceutical formulation IP.
What this case signals for the animal health IP landscape
A 26-day voluntary dismissal is rarely the end of the story — here is what patent professionals should monitor.
Voluntary dismissal without prejudice is a litigation tool, not a concession
Elanco’s use of Rule 41(a)(1)(A)(i) within 26 days suggests a deliberate tactical choice rather than an acknowledgment of weakness. Plaintiffs often file to preserve rights, trigger negotiation pressure, or probe a defendant’s posture before investing in full discovery. IP teams monitoring Elanco’s portfolio should note this case as an active enforcement signal for US7910122B2.
Pet IQ’s OTC product line remains under potential IP risk
Without a settlement agreement, licence, or with-prejudice dismissal on the public record, Pet IQ’s Pet Armor Extend products carry residual infringement risk. Companies in the OTC animal health space — particularly those with competing parasite treatment formulations — should conduct freedom-to-operate analysis against US7910122B2 and monitor for any refiling by Elanco in this or another jurisdiction.
Elanco v Pet — key questions answered
Elanco Animal Health filed an infringement action against Pet IQ in the Florida Middle District Court asserting US7910122B2 against Pet Armor Extend products. The case was voluntarily dismissed without prejudice by Elanco after just 26 days, on September 17, 2025, under Federal Rule of Civil Procedure 41(a)(1)(A)(i). No merits determination was made.
A voluntary dismissal without prejudice means Elanco’s infringement claims based on US7910122B2 were not adjudicated on the merits and are not barred from being refiled. Elanco retains the right to bring the same or similar claims against Pet IQ in the future. The dismissal is not an admission of weakness and does not resolve the underlying IP dispute over Pet Armor Extend products.
US7910122B2 (application US11/631089) is an Elanco-held patent in the animal health domain covering parasite treatment formulations for companion animals. Elanco asserted it against Pet IQ’s Pet Armor Extend products, suggesting the products may fall within the patent’s claim scope. The B2 designation indicates the patent has been subject to post-grant prosecution, with claims that have been examined and refined.
Yes. Because the dismissal was explicitly without prejudice under Rule 41(a)(1)(A)(i), Elanco is not barred from refiling infringement claims based on US7910122B2 against Pet IQ. A second voluntary dismissal without prejudice, however, would typically operate as a dismissal with prejudice under Rule 41(a)(1)(B). The public record does not indicate any settlement or licence that would preclude refiling.
The public record does not disclose the reason for the rapid dismissal. A 26-day lifecycle is consistent with several scenarios: early settlement or licensing discussions, a negotiated commercial resolution not disclosed publicly, a strategic decision to refile in a different venue, or a recalibration of litigation strategy. Because no defendant answer was filed and no court orders on substance were issued, the true reason remains undisclosed.
PatSnap Eureka searches patents and litigation data to answer instantly.